Tebentafusp: The First FDA-approved Monoclonal Antibody for Cancer Treatment in 2022

Thumbnail Image

Files

tms-1-4-123546.pdf (87.45 KB)

Date

2021-11-30

Authors



Journal Title

Journal ISSN

Volume Title

Publisher

Brieflands

DOI

https://doi.org/10.5812/tms.123546

Abstract

This article does not have an abstract.

Description

Keywords

Citation

URI

https://brieflands.com/journals/jai/articles/123546

Collections

Trends in Medical Sciences

Endorsement

Review

Supplemented By

Referenced By